<SEC-DOCUMENT>0001213900-25-004744.txt : 20250121
<SEC-HEADER>0001213900-25-004744.hdr.sgml : 20250121
<ACCEPTANCE-DATETIME>20250121063503
ACCESSION NUMBER:		0001213900-25-004744
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250121
FILED AS OF DATE:		20250121
DATE AS OF CHANGE:		20250121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALTERITY THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001131343
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-49843
		FILM NUMBER:		25540373

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000
		BUSINESS PHONE:		61 3 9349 4906

	MAIL ADDRESS:	
		STREET 1:		LEVEL 3, 460 BOURKE STREET
		CITY:			MELBOURNE
		STATE:			C3
		ZIP:			VIC 3000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRANA BIOTECHNOLOGY LTD
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0228001-6k_alterity.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>



<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
6-K</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF FOREIGN PRIVATE ISSUER</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PURSUANT
TO RULE 13a-16 OR 15d-163</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the month of    January 2025</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alterity
Therapeutics Limited</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of Principal Executive Office)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F &#9744;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm">333-251073</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm">333-248980</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm">333-228671</a>) and our
Registration Statements on Form F-3 (Files No. <a href="http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm">333-274816</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm">333-251647</a>, <a href="http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm">333-231417</a>
and <a href="http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm">333-250076</a>)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 2pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALTERITY
THERAPEUTICS LIMITED</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a
development stage enterprise)</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are submitted:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font-style: normal; vertical-align: top; text-align: justify; background-color: rgb(204,238,255); font-weight: normal">
<td style="font-style: normal; width: 9%; text-align: left; font-weight: normal">99.1</td>
    <td style="font-style: normal; width: 1%; font-weight: normal"><b>&nbsp;</b></td><td style="font-style: normal; text-align: justify; width: 90%; font-weight: normal"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="ea022800101ex99-1_alterity.htm">ATH shareholder newsletter January 2025.</A></P></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>SIGNATURE</u></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>Alterity Therapeutics Limited</b></font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 4%">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 36%">&nbsp;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">By:</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">/s/ Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Geoffrey P. Kempler</font></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font-family: Times New Roman, Times, Serif"><font style="font-size: 10pt">Chairman</font></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-transform: none; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
January 21, 2025</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif">&nbsp;</div></div><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea022800101ex99-1_alterity.htm
<DESCRIPTION>ATH SHAREHOLDER NEWSLETTER JANUARY 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Alterity Therapeutics Issues Shareholder Newsletter
Highlighting Pipeline Advances and Key Upcoming Milestones</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA
&ndash; 17 January 2025:</B> Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (&ldquo;Alterity&rdquo; or &ldquo;the Company&rdquo;), a biotechnology
company dedicated to developing disease modifying treatments for neurodegenerative diseases, has released a Shareholder Newsletter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You can access the full newsletter in this
link: https://mailchi.mp/we-worldwide/alterity-therapeutics-shareholder-newsletter-january-2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is an excerpt of the newsletter, a Letter
to Shareholders from CEO David Stamler:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Valued Shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we again begin a new year, I am filled with
optimism for 2025 and what lies ahead for Alterity Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I want to express my sincere gratitude for your
unwavering support and belief in our mission to develop disease-modifying therapies for those living with neurodegenerative diseases.
Your investment in Alterity allows us to pursue groundbreaking research and bring hope to patients and families affected by these devastating
conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2024 was a year of significant progress for
Alterity. </B>Most prominently, we completed our 12-month, double-blind Phase 2 clinical trial of ATH434 in early-stage Multiple System
Atrophy (MSA). This milestone leads us to a topline data readout expected in late January or early February. Last July, we were pleased
to report encouraging preliminary results from our open-label biomarker study in individuals with more advanced MSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preliminary results from the open-label study
showed that individuals receiving 6-months treatment with ATH434 had stable or improved clinical measures and that this clinical benefit
was supported by biomarker data: stable iron levels and brain volumes in clinical responders and reduced neuronal injury compared to untreated
patients from our MSA natural history study. Taken together, these data provide strong support for the potential of ATH434 to slow the
progression of this very aggressive disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to our advancements in clinical studies,
we also continue to generate compelling data in MSA and other neurological diseases. Last year, we presented promising preclinical data
demonstrating the potential of ATH434 in a primate model of Parkinson's disease. Our bioMUSE Natural History study, in collaboration with
Professor Daniel Claassen&rsquo;s neuroimaging group at Vanderbilt University Medical Center, yielded valuable insights into MSA progression
and led to the development of a novel imaging biomarker for assessing brain volume in regions affected by MSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This year promises to be pivotal for Alterity
with topline data expected from both of our Phase 2 clinical trials in MSA.</B> Our team remains steadfast in their dedication to advancing
our research and development efforts and bringing innovative therapies to patients with neurodegenerative diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for your continued interest and support
and we look forward to keeping you updated on our progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">David Stamler, M.D., Chief Executive Officer of
Alterity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Alterity Therapeutics Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alterity Therapeutics is a clinical stage biotechnology
company dedicated to creating an alternate future for people living&nbsp;with neurodegenerative diseases. The Company&rsquo;s lead asset,
ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple
System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology
of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please
visit the Company&rsquo;s web site at www.alteritytherapeutics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorisation &amp; Additional information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor and Media Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Australia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ana Luiza Harrop</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">we-aualteritytherapeutics@we-worldwide.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+61 452 510 255</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Remy Bernarda</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">remy.bernarda@iradvisory.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (415) 203-6386</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release contains &quot;forward-looking
statements&quot; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.
The Company has tried to identify such forward-looking statements by use of such words as &quot;expects,&quot; &quot;intends,&quot; &quot;hopes,&quot;
&quot;anticipates,&quot; &quot;believes,&quot; &quot;could,&quot; &quot;may,&quot; &quot;evidences&quot; and &quot;estimates,&quot; and
other similar expressions, but these words are not the exclusive means of identifying such statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Important factors that could cause actual results
to differ materially from those indicated by such forward-looking statements are described in the sections titled &ldquo;Risk Factors&rdquo;
in the Company&rsquo;s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including,
but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation,
progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other
statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks
and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing
of the Company&rsquo;s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future
sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but
not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's
intellectual property or trade secrets, the uncertainty of successfully enforcing the Company&rsquo;s patent rights and the uncertainty
of the Company freedom to operate.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Any forward-looking statement made by us in
this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as
a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V -T# 2(  A$! Q$!_\0
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M]SL335T%>/?'KQ-]DT:T\/0/B6\;SIP#TC4\#\6_]!KU]W2*-I'8*B@LS$\
M#O7RAKEUJ_Q%^(%]=Z/:RW<FXFWC4#Y84("GGCT/U-7!7=P9M>+/AV=$^%VA
M:RL.V\!W7W'.)>4S_N\+^->R?"[Q+_PDW@>SFE?==VH^S7&3R64<'\5P?SKR
M74+/XPZKI\UA?6U[-:SKMDC98<$?A3/@WKD_AKQU/H.H!H5O28'C?C9.A.W/
MZK^(JFKQ W/VA_\ 6:!])O\ V2NN\3V_B>?X<:*WABZ^SS16L;W#;PN8A#R.
M??%<C^T/_K- ^DW_ +)7JUA&\W@&UBC&7?2T51ZDQ"I>D4!\W_#NQ\8WUSJ
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M^#(_#BW32*EL]OYY3!^;/./QHHHN!3\,>%K_ ,.^3$VJP7%I%"(1&E@D3L
M 2X.3T_&H]>\ :9XCU6^O=1VR_:;%;2-3$"T!#%A(C'H>?THHIW8&R^FWC^&
M3I?V\)=&V\C[6D(&#C&X)G /M6#8?#NSTB^TB\T[4K])-.RBK/*94:)AAD"D
MX7/!X[BBBBX&GKGA.Q\0ZSIE[J"13P6*R@VLL0=)"X R<],8S6O%8VUK8?8K
M2"*W@"%$CB0*J@^@'%%%(#F/"O@Z^\,?9H5U>">S@C,?EBP2.1AVS(#GKS^%
M7=:\-W5[K<&LZ5JK:=?QV[6SL8!,DD9;=@J2.0>0<T44[@7O#VB1>'M%ATZ*
M:2?86=YI/O2.S%F8X]233=)T-=*U+5[P3F0ZC<"<J5QLPBKCW^[112 $T-4\
M6RZ]]H8L]DMIY.W@ .6W9_'&*S[[PO>C6[G5M$UEM-FO$5;J-K=9HY"HPK@$
MC# <>A]***=P-6^L+RYT7['!J+0W6Q5-TT*ON(QG*'@@\Y'O63X<\'C1+K4+
<RXNTGNKXQ^9]GMUMXU" @813UY.23S112 __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
